Autres langues 89bio, Inc.

Actions

ETNB

US2825591033

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/05/2024			Varia. 5j.	Varia. 1 janv.
8,63 ^USD	-3,79 %		-0,92 %	-22,74 %

14/05	89Bio lance l'étude de phase 3 Enlighten-Cirrhosis sur la pegozafermine chez des patients atteints de stéatohépatite associée à un dysfonctionnement métabolique (MASH) avec cirrhose compensée	CI
10/05	89BIO, INC. : HC Wainwright optimiste sur le dossier	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis	14/05
89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis Patients with Compensated Cirrhosis	14/05
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	10/05
89bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update	09/05
89bio to Participate in the BofA Securities 2024 Health Care Conference	08/05
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH	02/05
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors	17/04
89bio, Inc. Appoints Martin Babler to Its Board of Directors	17/04
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/04
89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing	03/04
Sector Update: Health Care Stocks Gain Wednesday Afternoon	27/03
89bio's Liver Disease Drug Candidate Pegozafermin Gets EMA Priority Medicines Status	27/03
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis	27/03
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis	27/03
89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis and Compensated Cirrhosis	27/03
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis	12/03
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis	12/03
89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis, Formerly Known as Nonalcoholic Steatohepatitis	12/03
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(4)	11/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues 89bio, Inc.

Actions

ETNB

US2825591033

Autres langues

Filtres